05:08 AM EST, 02/10/2025 (MT Newswires) -- Pliant Therapeutics ( PLRX ) said late Friday it has suspended enrollment and treatment in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis following a recommendation from the trial's data safety monitoring board.

The company said it is analyzing data to better understand the board's reasoning.

"Blinding of the study will be maintained to preserve trial integrity," Pliant Therapeutics ( PLRX ) said.

The company's shares were down 54% in Monday premarket activity.